The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2016 | First results from BGB-3111 in CLL and Waldenström’s macroglobulinemia
Constantine Tam, MD from the Peter MacCallum Cancer Centre, Melbourne, Australia gives an overview of the Phase I trial of BTK inhibitor BGB-3111 (zanubrutinib) in chronic lymphocytic leukemia (CLL) and Waldenström’s macroglobulinemia. BGB-3111 is similar to ibrutinib as it binds the same active sites irreversibly. It is, however, more specific and selective for BTK. In the CLL patients, the drug is well-tolerated and they demonstrated complete tissue inhibition of BTK. The response rate is 96% with no complete remissions (CR) to date. In Waldenström’s macroglobulinemia, deep BTK inhibition was achieved with a response rate of 94% and very good partial response rate (VGPR) of 34%. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
